Canavan disease: a review of recent developments

Area of Science:

• Genetics and Neurology
• Biochemistry
• Medical Research

Background:

• Canavan disease is an autosomal recessive inherited neurological disorder.
• It results from mutations in the aspartoacylase gene on chromosome 17.
• The disease causes central nervous system damage due to aspartoacylase deficiency and N-acetylaspartate accumulation.

Purpose of the Study:

• To review the clinical features, causes, and potential treatments for Canavan disease.
• To explore diagnostic methods and emerging therapeutic strategies, including gene therapy.

Main Methods:

• Review of existing literature on Canavan disease clinical presentation and pathophysiology.
• Discussion of diagnostic techniques: N-acetylaspartate measurement in amniotic fluid, urine, blood, and spinal fluid; DNA analysis; proton magnetic resonance spectroscopy; and neuroradiology.
• Evaluation of preliminary gene therapy approaches in preclinical models (knockout mice) and early clinical observations.

Main Results:

• Canavan disease diagnosis confirmed by elevated N-acetylaspartate levels and white matter degeneration on imaging.
• Gene therapy shows potential for modifying brain cell phenotypes, appearing well-tolerated with positive biochemical, radiological, and clinical changes.
• Canavan disease knockout mice are crucial for developing gene transfer vectors and understanding disease mechanisms.

Conclusions:

• Canavan disease diagnosis is achievable through metabolic and genetic testing, with prenatal diagnosis possible.
• Gene therapy represents a promising, albeit unproven, therapeutic avenue for Canavan disease.
• Further research using animal models is essential for advancing gene therapy and understanding the disease's pathophysiology.